⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996404 | 1.00 | — | — | |
| SCHEMBL51621 | 1.00 | — | — | |
| SCHEMBL25443681 | 0.96 | — | — | |
| SCHEMBL17379548 | 0.83 | CHRM2 (0.35) | — | |
| SCHEMBL17379528 | 0.83 | CHRM2 (0.35) | — | |
| SCHEMBL17379281 | 0.83 | CHRM2 (0.35) | — | |
| SCHEMBL6052755 | 0.78 | — | — | |
| SCHEMBL10314719 | 0.78 | — | — | |
| SCHEMBL10314713 | 0.78 | — | — | |
| SCHEMBL13949952 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350419-A | Oxysterol and methods of use thereof | 萨奇治疗股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368214-A1 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-114478677-B | Oxysterol and methods of use thereof | 萨奇治疗股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4392432-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028278-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-110267960-A | Substituted pyrazolo [1,5-a] pyrazine compound as RET kinase inhibitor | 阿雷生物药品公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-103012463-B | (S) synthetic method of-3-methyl-2-(tertiary butyl dimethyl Si base)-1-n-butyl bromide | NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-103122009-B | Two kinds of important intermediate compounds for the synthesis of Tacalcitol side chain | Jiangsu Jibeier Pharmaceutical Co., Ltd. (CN) | 2015-11-25 | — | — | CN | disclosed |
| US-8946188-B2 | Anti-microbial agents and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140024611-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-01-23 | — | — | US | disclosed |
| US-6326503-B1 | ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-12-04 | — | — | US | disclosed |
| US-6184398-B1 | ANTITUMOR AGENTS AND TREATMENT OF RHEUMATIC CONDITIONS; HIGH BINDING ABILITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY; E.G.,1,3-DIHYDROXY-20-3-HYDROXY-3-METHYLBUTYLTHIO)-9,10-SECOPREGNA -5,7,10(19),16-TETRAENE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-1047671-A1 | METHOD OF PREPARATION OF CHOLECALCIFEROL DERIVATIVES AND NEW INTERMEDIATE COMPOUNDS | INSTYTUT FARMACEUTYCZNY (PL) | 2000-11-02 | — | — | EP | disclosed |
| EP-0947504-A1 | 16-ENE-VITAMIN D DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999036400-A1 | METHOD OF PREPARATION OF CHOLECALCIFEROL DERIVATIVES AND NEW INTERMEDIATE COMPOUNDS | INSTYTUT FARMACEUTYCZNY (PL) | 1999-07-22 | — | — | WO | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |